SCHEMBL208100

SCHEMBL208100

Fc1ccc(-c2csc(Nc3ccc(Cc4ccccc4)cc3)n2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.78
ALOX5 P09917 7/20 0.66
SMN1; SMN2 Q16637 7/20 0.65
MAPT P10636 6/20 0.65
RAB9A P51151 5/20 0.65
NPC1 O15118 3/20 0.65
TDP1 Q9NUW8 2/20 0.65
POLB P06746 1/20 0.65
MEN1 O00255 6/20 0.59
KMT2A Q03164 6/20 0.59
MAPK1 P28482 1/20 0.59
AMY1A P0DUB6 2/20 0.58
VCP P55072 1/20 0.58
GAA P10253 3/20 0.55
ALDH1A1 P00352 2/20 0.55
LMNA P02545 2/20 0.55
USP2 O75604 1/20 0.55
THRB P10828 1/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207509 0.89 NPY5R (0.72) NPY5RALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL29276759 0.88 NPY5R (1.00) NPY5RALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL1820221 0.88 NPY5R (0.88) NPY5RALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL207417 0.87 ALOX5 (0.78) NPY5RALOX5SMN1; SMN2MAPTNPC1
SCHEMBL6926815 0.86 ALOX5 (0.85) NPY5RALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL31126423 0.84 ALOX5 (0.69) NPY5RALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL207176 0.83 AGER (0.61) NPY5RSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL205699 0.82 NPY5R (0.78) NPY5RALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL4543081 0.82 ALOX5 (0.66) NPY5RALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL207355 0.81 ALOX5 (0.68) NPY5RALOX5SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 NPY5R 3686/4885ALOX5 3410/4885SMN1; SMN2 3252/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 NPY5R 3686/4885ALOX5 3410/4885SMN1; SMN2 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.